Psychoactive cannabinoids: THC, CBD and the CB1 receptor

Two molecules, one very different answer

Draw cannabidiol and tetrahydrocannabinol side by side and the two pictures look almost interchangeable. Same building blocks, one small rearrangement. Only one of them, though, is the constituent that Gaoni and Mechoulam isolated in 1964 and described as the intoxicating one in cannabis [1]. That single difference is the whole question, and everything below is the detail behind it.

The word psychoactive gets used loosely on shelves and in forum threads. The published record is narrower, and a lot older than the market built on top of it.

1. THC was isolated, characterised and partly synthesised in 1964 by Gaoni and Mechoulam, who identified it as the active, intoxicating constituent of cannabis [1].
2. CBD reached the literature first. Its structure was established in 1940 by Adams, Hunt and Clark [2], and it is conventionally classed as non-intoxicating.
3. Cannabis intoxication tracks THC content [1]. No other cannabinoid printed on a certificate of analysis stands in for it or does the same job in that calculation.
4. Concentration belongs in the answer too. Fractions of a percent and 20% are not the same quantity, and nobody in Europe reads them the same way.
5. A full-spectrum hemp extract can carry CBD, CBG, CBC, CBN and CBDV in the same bottle, and none of those shows the CB1 engagement described for THC [1] [3].
6. The distinction is mechanistic, not stylistic. It rests on receptor work published in 1990, which is the next section [3].

So the short version, before the biology: one intoxicating cannabinoid in the record from 1964 [1], and a much longer list of cannabinoids classed as non-intoxicating alongside it [2] [3]. Two words, two very different columns.

The receptor described in 1990

In 1990, Matsuda and colleagues reported the structure of a cannabinoid receptor and the functional expression of its cloned cDNA [3]. Before that paper, the difference between cannabinoids was a description. After it, there was a protein to point at.

The protein carries the designation CB1. It is not exotic hardware bolted on for cannabis; it is part of the body's own endocannabinoid system, with its own signalling molecules.

1. CB1 is found at high density in brain regions handling memory, movement and the processing of sensory information [3].
2. The system it belongs to has endogenous ligands, meaning molecules the body makes itself: anandamide and 2-AG.
3. THC binds CB1 directly and activates it, and that direct engagement is where its intoxicating character comes from [1] [3].
4. The other cannabinoids commonly tabled on a hemp analysis show no equivalent CB1 engagement, which is the mechanistic basis for calling them non-intoxicating [3].
5. CBD's structure had already been on record for fifty years when that receptor was described [2] [3]. The classification arrived later than the molecule.
6. This is also why the answer does not shift with brand, format or marketing language. Receptor behaviour is a property of the molecule, not of the bottle it arrives in [3].

Worth being plain about the limits here. The 1990 work maps a receptor and its expression [3]; it is not a catalogue of what every minor cannabinoid does in a human being. We have been working with cannabinoids since 2014, and the honest position on several of the minor ones is still that the human data is thin. Where the evidence is settled, it is settled at CB1.

Names that look alike on a certificate

A batch report is a list of very similar words. CBD, CBDV, CBG, CBN, THC, THCV. Read quickly, they blur. Read carefully, one of them is the one written into law.

Nothing about a plant, an oil's colour or a smell sorts them. Only the analysis does.

1. CBD and THC differ by a minimal atomic rearrangement, yet their behaviour at CB1 is not comparable [2] [3].
2. THCV is a close relative of THC by name and by structure, and neither one can be picked out by appearance. The chromatogram separates them; the eye does not.
3. Because the names are near-identical, the useful habit is reading the column headings on a report rather than the front of the packaging.
4. Our page on what THC is follows that single molecule from the 1964 isolation onwards, if you want the compound on its own rather than in a comparison [1].
5. The CB1 receptor has a page of its own too, and it is the more useful one to read if the part you are stuck on is why the non-intoxicating label holds at all [3].
6. Every Cibdol batch is analysed by an independent laboratory, so the cannabinoid breakdown is something you can check before the bottle becomes part of a routine, not after.

That is the Swiss habit applied to a naming problem. The molecules are almost impossible to tell apart in ordinary language, so we let a measurement do the talking. Since 2014, one standard: know what is inside, and be able to show it. Claims are easy. Reports are better.

What the number on the bottle covers

Two figures usually appear on a hemp product. A cannabinoid strength, and a THC content. They answer different questions, and only one of them connects to the intoxication question at all [1].

Here is the reading order that removes the most uncertainty.

1. Check whether a THC figure is stated. If it is absent, its absence is not a value, and you have not learned anything about it.
2. Check what the strength percentage refers to. Fractions of a percent and 20% describe different orders of magnitude in the same size bottle.
3. Note that EU and UK limits are written around THC content specifically, not around cannabinoids in general.
4. That wording lines up with the receptor evidence: the quantity the rules count is the one with direct CB1 activity [1] [3].
5. No cannabinoid on the list substitutes for THC in that calculation, so a high CBD, CBG or CBN figure tells you nothing about the regulated number.
6. Where a batch report is published, the THC line and the cannabinoid profile appear on the same document, which is the point of publishing it.

Cibdol products are formulated to sit within those legal THC limits, and they are non-intoxicating [1] [3]. Said plainly, because it is the question most people arrive with, and because a vague answer to it is worse than no answer. The regulated compound has a name, a date of characterisation and a receptor. The rest of the profile is measured and printed. Nature, made precise.

Three papers, read in order

The whole distinction rests on three publications spread across half a century. Read in date order, they build a chain: a structure, an active constituent, a receptor.

What each paper fixes

The 1940 work of Adams, Hunt and Clark established the structure of cannabidiol from a hemp extract [2]. In 1964, Gaoni and Mechoulam isolated the active constituent of hashish, gave it a structure and a partial synthesis, and pinned intoxication to that specific molecule [1]. Then 1990: Matsuda and colleagues published the structure of a cannabinoid receptor and the functional expression of its cloned cDNA, giving the CB1 designation something concrete behind it [3]. THC engages that receptor directly [1] [3]. The commonly listed alternatives do not show equivalent engagement [3], which is what the non-intoxicating column on any comparison table actually means.

What they leave open

Quite a lot, and it is worth saying so. Those three papers describe two molecules and one receptor. They do not quantify what each minor cannabinoid does in humans, and CBN, CBG, CBC, CBDV and THCV each sit on a much shorter research record than THC or CBD. Structural closeness is not a prediction either: THCV resembles THC on paper, and resemblance is not receptor data. So the classification stands where the evidence stands, at CB1 [3], and stops where the evidence stops. When new work changes that picture, we change with it. That has been the approach since 2014, and it is the reason we would rather point you at a batch report than at an adjective.